↓ Skip to main content

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, April 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

2 news outlets
5 tweeters


248 Dimensions

Readers on

176 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Published in
Journal for Immunotherapy of Cancer, April 2015
DOI 10.1186/s40425-015-0057-1
Pubmed ID

Heinz Läubli, Cathrin Balmelli, Matthias Bossard, Otmar Pfister, Kathrin Glatz, Alfred Zippelius


Antibodies that stimulate the immune system by targeting inhibitory T cell receptors were successfully introduced into oncological practice and are capable to overcome tumor-induced immune evasion. In particular, targeting of the inhibitory receptors CTLA-4 and PD-1 or its ligand PD-L1 have been shown to be beneficial for patients with melanoma, renal cell cancer, non-small cell lung cancer and a growing list of other cancers with impressive response rates. Here, we report a severe, potentially life-threatening side effect of anti-PD-1 immunotherapy with pembrolizumab, which has not been previously described in the literature. A 73-year-old woman with metastatic uveal melanoma treated with pembrolizumab in third line developed severe heart failure due to pembrolizumab-mediated autoimmune myocarditis. Echocardiographic studies revealed a severely impaired left ventricular function with dyssynchrony. All tests for cardiotropic viruses were negative and histological analysis of a myocardial biopsy showed lymphocytic infiltration with a predominance of CD8 positive cells and a reduction of FOXP3 positive regulatory T cells. After initiation of corticosteroids and guideline-conform heart failure therapy, the symptoms rapidly improved and the left ventricular function recovered. While autoimmune myocarditis is a documented side effect of other checkpoint inhibitors, as for example ipilimumab and in one case with anti-PD-L1 antibody, it is not described for anti-PD-1-antibodies like pembrolizumab or nivolumab. As the FDA recently approved both pembrolizumab and nivolumab for melanoma progressing after anti-CTLA-4 treatment with ipilimumab, more patients will soon receive anti-PD-1 therapy. Thus, it is important to be aware of such rare, but severe immune-related adverse events.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 2 1%
Denmark 1 <1%
Brazil 1 <1%
Unknown 172 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 34 19%
Other 19 11%
Student > Doctoral Student 19 11%
Student > Ph. D. Student 17 10%
Student > Postgraduate 16 9%
Other 35 20%
Unknown 36 20%
Readers by discipline Count As %
Medicine and Dentistry 84 48%
Agricultural and Biological Sciences 13 7%
Immunology and Microbiology 10 6%
Biochemistry, Genetics and Molecular Biology 10 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 2%
Other 11 6%
Unknown 44 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2021.
All research outputs
of 21,732,065 outputs
Outputs from Journal for Immunotherapy of Cancer
of 2,683 outputs
Outputs of similar age
of 244,383 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
of 1 outputs
Altmetric has tracked 21,732,065 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,683 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,383 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them